Physician profile
Mackenzie E Jenkinson
NPI 1760771190
$494.00
in general payments reported to CMS, 2019-2025
12 companies · $158 in 2025
The $158 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.35 · 2020: $47.03 · 2023: $84.51 · 2024: $162 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $404.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $201.73 | 2023-2025 | Azstarys |
| Sanofi Pasteur INC. | $56.58 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.62 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $38.70 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $31.39 | 2019-2023 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $22.63 | 2025 | Zoryve |
| Pfizer INC. | $22.30 | 2024 | |
| Tris Pharma INC | $17.67 | 2023 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $17.40 | 2025 | Relexxii |
| Seqirus USA INC | $15.51 | 2023 | Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $13.15 | 2024 | Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Jenkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.